Semaglutide

GLP-1 / MetabolicResearch Use Only

Also known as: Ozempic (brand), Wegovy (brand), Rybelsus (brand)

The GLP-1 in Ozempic/Wegovy — quiets appetite and slows digestion. Slow titration is the whole game.

Dosing quick reference

research reference

Starting dose

0.25 mg once weekly

Frequency

Once weekly (same day)

Typical range

0.25–2.4 mg per week

Cycle

16–20+ weeks of gradual escalation

Titration (step-up)

Wk 1–4: 0.25 → Wk 5–8: 0.5 → Wk 9–12: 1.0 → Wk 13–16: 1.7 → Wk 17+: 2.4 mg

Never skip titration steps — they exist to manage nausea.

Half-life

~7 days

Route

Subcutaneous (research)

Common use

Metabolic and weight-management research

Common vial sizes

5 mg · 10 mg · 20 mg

Storage

Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.

Stacking notes

In research discussions it is sometimes referenced alongside cagrilintide (as a combined amylin/GLP-1 approach). Combining metabolic agents can compound gastrointestinal effects.

Reported side effects

NauseaReduced appetiteGastrointestinal upsetConstipation or diarrhea

Regulatory note: Prescription drug in Canada and the US; approved for type 2 diabetes and chronic weight management under brand names. Research-grade material is not for human use.

Calculate a dose →Semaglutide on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.